Prime Medicine Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
PRME$4.30-7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets F-
CONSOLIDATED BALANCE SHEETS
| December 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2024 | 2023 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $182,476 | $41,574 |
| Short-term investments | 2,998 | 74,639 |
| Short-term investment — related party | 4,968 | 5,452 |
| Prepaid expenses | 6,777 | 19,057 |
| Other current assets | 14,667 | 2,254 |
| Total current assets | 211,886 | 142,976 |
| Property and equipment, net | 24,404 | 22,659 |
| Operating lease right-of-use assets | 47,156 | 13,941 |
| Restricted cash | 14,062 | 13,496 |
| Other assets | — | 779 |
| Total assets | $297,508 | $193,851 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $11,351 | $19,537 |
| Accrued expenses and other current liabilities | 15,904 | 14,110 |
| Accrued settlement payment — related party | — | 13,500 |
| Deferred revenue — related party | 7,092 | — |
| Operating lease liability | 3,614 | 9,276 |
| Total current liabilities | 37,961 | 56,423 |
| Deferred revenue, net of current — related party | 63,218 | — |
| Operating lease liability, net of current | 37,180 | 4,357 |
| Research and development funding liability | 6,000 | — |
| Total liabilities | 144,359 | 60,780 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.00001 per share; 775,000,000 shares authorized; 131,160,842 and 97,377,121 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 2 | 2 |
| Additional paid-in capital | 840,358 | 624,414 |
| Accumulated other comprehensive loss | 1 | (15) |
| Accumulated deficit | (687,212) | (491,330) |
| Total stockholders’ equity | 153,149 | 133,071 |
| Total liabilities and stockholders’ equity | $297,508 | $193,851 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.